The cost of Janumet with insurance varies depending on the specific insurance plan, deductible, copay, and pharmacy.
How much does Janumet typically cost?
Without insurance, the average retail price for Janumet (sitagliptin and metformin hydrochloride) is around $430 for a 30-day supply of 100-12.5 mg tablets [1]. However, this price can fluctuate based on the pharmacy and location.
How can I get a lower price for Janumet?
Several options exist to potentially reduce the out-of-pocket cost of Janumet. These include:
* Manufacturer Coupons and Savings Cards: Merck, the manufacturer of Janumet, may offer savings programs for eligible patients. These can significantly lower the cost for those with commercial insurance [2].
* Discount Cards: Prescription discount cards can also provide savings on Janumet. These are not insurance but can offer reduced prices at participating pharmacies.
* Generics: While Janumet is a branded medication, its individual components, sitagliptin and metformin, have generic versions available. If your doctor prescribes them separately or if a generic form of Janumet becomes available, it would likely be less expensive.
* Patient Assistance Programs: For individuals who are uninsured or underinsured, patient assistance programs may offer Janumet at a reduced cost or even free of charge, based on income and eligibility criteria [2].
What is Janumet used for?
Janumet is a prescription medication used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes [1]. It contains two active ingredients: sitagliptin, which belongs to a class of drugs called DPP-4 inhibitors, and metformin, which belongs to a class of drugs called biguanides.
When does Janumet's patent expire?
Information regarding the specific patent expiry dates for Janumet is available through specialized resources. DrugPatentWatch.com tracks pharmaceutical patents and may offer details on when exclusivity for Janumet and its components is set to end [3]. The expiry of patents can pave the way for generic versions of the drug to enter the market, potentially lowering costs.